Biomarkers
CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
Scientific Reports 2021. June 15 [Link] Masayuki Watanabe, Tomohito Higashi, Kana Ozeki, Atsuko Y Higashi, Kotaro Sugimoto, Hayato Mine, Hironori Takagi, Yuki Ozaki, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Yutaka Shio, Hiroyuki Suzuki, Hideki Chiba Abstract Malignant mesothelioma is a cancer with a poor survival rate. It is difficult to diagnose mesotheliomas because…
Read MoreOxytocin receptor is a promising therapeutic target of malignant mesothelioma
Cancer Science 2021 June 11 [Link] Yuta Kodama, Ichidai Tanaka, Tatsuhiro Sato, Kazumi Hori, Soei Gen, Masahiro Morise, Daisuke Matsubara, Mitsuo Sato, Yoshitaka Sekido, Naozumi Hashimoto Abstract Malignant mesothelioma (MM) is one of the most aggressive tumors. We conducted bioinformatics analysis using Cancer Cell Line Encyclopedia (CCLE) datasets to identify new molecular markers in MM.…
Read MoreImmune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma
Drugs 2021 June [Link] Wanyuan Cui, Sanjay Popat Abstract Immune checkpoint inhibitors (ICI) have shown important but variable efficacy in mesothelioma despite a lack of strong biological rationale. Initial trials assessed ICI monotherapy in patients with relapsed mesothelioma, with objective response rates (ORR) between 4.5 and 29%, median progression-free survival (PFS) between 2.5-6.2 months, and…
Read MorePathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma
Cancers 2021 May 24 [Link] Francesca Napoli, Angela Listì, Vanessa Zambelli, Gianluca Witel, Paolo Bironzo, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi Abstract Malignant pleural mesothelioma (MPM) is a rare and highly aggressive disease that arises from pleural mesothelial cells, characterized by a median survival of approximately 13-15 months after diagnosis. The primary cause…
Read MoreNIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
Journal of Translational Medicine 2021 May 31 [Link] Vilde Drageset Haakensen, Anna K Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana M Cedres, Åslaug Helland Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoperable disease, few treatment options are…
Read MoreDevelopment of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation
Lung Cancer 2021 July [Link] Xiao-Jie Xie, Si-Yun Liu, Jian-You Chen, Yi Zhao, Jie Jiang, Li Wu, Xing-Wen Zhang, Yi Wu, Hui Duan, Bing He, Heng Luo, Dan Han Abstract Objectives: We aimed to explore the feasibility of 2D and 3D radiomics signature based on the unenhanced computed tomography (CT) images to predict BRCA1-associated protein…
Read MoreAssessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma
Cancer Immunology, Immunotherapy 2021 May 18 [Link] Beatrice Dozin, Grazia Carbotti, Silvio Roncella, Paola Ferro, Paolo Dessanti, Pier Aldo Canessa, Silvano Ferrini, Marina Fabbi Abstract Backgound: Literature reports suggest that the host immune system may control Malignant Pleural Mesothelioma (MPM) growth, although its activity is limited by regulatory mechanisms. In this retrospective study, we analyzed…
Read MoreThe usefulness of biomarkers in diagnosis of asbestos-induced malignant pleural mesothelioma
Human & Experimental Toxicology 2021 May 17 [Link] Zübeyde Tanrıverdi, Fatih Meteroglu, Hande Yüce, Abdurrahman Şenyiğit, Mümtaz Işcan, Songül Unüvar Abstract Introduction: Malignant pleural mesothelioma (MPM) is a malignant tumor that is associated mostly with asbestos exposure. The present study was to evaluates the diagnostic value of neopterin, periostin, YKL-40, Tenascin-C (TNC), and Indolamine 2,3-dioxygenase…
Read MoreThe usefulness of biomarkers in diagnosis of asbestos-induced malignant pleural mesothelioma
Human and Experimental Toxicology 2021 May 17 [Link] Zübeyde Tanrıverdi, Fatih Meteroglu, Hande Yüce, Abdurrahman Şenyiğit, Mümtaz Işcan, Songül Unüvar Abstract Introduction: Malignant pleural mesothelioma (MPM) is a malignant tumor that is associated mostly with asbestos exposure. The present study was to evaluates the diagnostic value of neopterin, periostin, YKL-40, Tenascin-C (TNC), and Indolamine 2,3-dioxygenase…
Read MoreCombined Analysis of RNA Sequence and Microarray Data Reveals a Competing Endogenous RNA Network as Novel Prognostic Markers in Malignant Pleural Mesothelioma
Frontiers in Oncology 2021 April 23 [Link] Weicheng Duan, Kang Wang, Yijie Duan, Xiuyi Chen, Xufeng Chu, Ping Hu, Bo Xiong Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with short survival time. Unbalanced competing endogenous RNAs (ceRNAs) have been shown to participate in the tumor pathogenesis and served as biomarkers for the…
Read More